OncoPrime is a Phenotypic Drug Discovery Platform with a full array of characterizations relevant to disease phenotype and vital for studying the drug response in native state

Our flagship product / platform as a service for accelerating drug discovery with the help of primary cells isolated from tumor tissue biopsy

NEW ORLEANS—Larger tumor size is associated with high-grade pathology in patients with pT1a renal cell carcinoma (RCC), according to study findings presented at the 2015 American Urological Association annual meeting. Jeffrey A. Larson, MD, of the Washington University School of Medicine in St. Louis, Mo., and colleagues identified 975 patients with T1a N0M0 RCC treated […]

The combination of antiangiogenic therapy and cytotoxic chemotherapy is active and well tolerated in patients with sarcomatoid and poor-risk renal cell carcinoma (RCC), a recent study published online this week in the journal Cancer has shown. This single-arm, phase 2 trial evaluated the activity of sunitinib and gemcitabine combination in 39 patients with sarcomatoid RCC […]

linicians now have a better picture of what may be the optimal first-line therapy for patients with metastatic non-clear cell renal cell carcinoma (NC-RCC), according to results from a randomized phase 2 international trial of everolimus compared with sunitinib. Investigators reported at the 2015 American Society of Clinical Oncology Annual Meeting that sunitinib was superior […]